Abstract
s / Journal of Reproductive Immunology 101–102 (2014) 40–60 43 whom markers other than interleukins were determined (n=88); first-trimester pregnant women in whom only interleukins were determined (n=80). These subgroups were subsequently divided according to the development of pregnancy in the third trimester. Each subgroup consists of an equal number of pathological and physiological pregnancies. Measured markers: Serum anti-cardiolipin autoantibodies IgG (ACLA-G) and IgM (ACLA-M), interleukins: IL-6, IL-12, IL-15, IL-16, IL-17, IL-18, and IL-23 (by a standard ELISA). Results: In group C the percentage of IL-6 (p=0.002), IL-18 (p=0.016), IL-23 (p=0.002), and ACLA-G (p<0.001) were higher. In other pathological conditions only the percentage of ACLA-M was higher (p<0.001). IL-15 was positive only in the patients who developed either severepreeclampsia or preeclampsia combinedwith lupus syndrome in the third trimester. IL-16 was elevated only in group a. Other parameters did not differ significantly. Conclusions: The positivity of some of the followed interleukins, rheumatoid factor and ACLA-G may indicate that the immune mechanism plays a key role in the onset of the pathophysiological chain of preeclampsia. We concluded that elevated biochemical and immunological markers can help to predict the threat of preeclampsia in the third trimester. Some markers can probably predict the development of particularly severe pathological conditions. Acknowledgement: This research was supported by PRVOUK – P25/LF1/2; MZCR – RVO – VFN 64165; PRVOUK – P32. http://dx.doi.org/10.1016/j.jri.2013.12.037
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have